Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381348 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30673511 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29725684 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30067164 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30678552 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL24632196 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL2624852 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL31114965 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29330492 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL13663954 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2025-10-28 | — | — | US | claimed |
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA MEDICAL UNIVERSITY (JP) | 2025-03-27 | — | — | US | claimed |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | SHOWA UNIVERSITY (JP) | 2024-11-12 | — | — | US | claimed |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | claimed |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | claimed |
| CN-118084942-B | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-06-13 | — | — | US | claimed |
| CN-118084942-A | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4337193-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | Biogen MA Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4326258-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117295497-A | Pharmaceutical composition for treating cerebral infarction | 渤健马萨诸塞州股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-11850232-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | BIOGEN MA INC. (US) | 2023-12-26 | — | — | US | claimed |
| EP-4252752-A1 | DRUG FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE, AND METHOD FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE USING SAID DRUG | Biogen MA Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| CN-116761600-A | Medicament for treating or preventing cerebral hemorrhage and method for treating or preventing cerebral hemorrhage using the same | 渤健马萨诸塞州股份有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | claimed |
| WO-2022240810-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | BIOGEN MA INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022226013-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | BIOGEN MA INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | claimed |
| CN-114126711-A | Medicament and method for treating or preventing diabetic complications using the same | 学校法人昭和大学 | 2022-03-01 | — | — | CN | claimed |
| US-20260144792-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ HUMAINES S.E.C. (CA) | 2026-05-28 | — | — | US | disclosed |
| CN-121620505-A | SMTP-7 derivative and preparation method of intermediate thereof | 上海森辉医药有限公司 | 2026-03-06 | — | — | CN | disclosed |
| CN-121620505-A | SMTP-7 derivative and preparation method of intermediate thereof | 上海森辉医药有限公司 | 2026-03-06 | — | — | CN | disclosed |
| WO-2026017006-A1 | METHODS FOR PRODUCTION OF SMTP-7 AND INTERMEDIATES USED IN THE METHODS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2026-01-22 | — | — | WO | disclosed |
| WO-2026017006-A1 | METHODS FOR PRODUCTION OF SMTP-7 AND INTERMEDIATES USED IN THE METHODS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2026-01-22 | — | — | WO | disclosed |
| CN-121064220-A | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-12-05 | — | — | CN | disclosed |
| CN-121064221-A | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-12-05 | — | — | CN | disclosed |
| CN-121064221-A | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-12-05 | — | — | CN | disclosed |
| CN-121064220-A | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-12-05 | — | — | CN | disclosed |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2025-10-28 | — | — | US | disclosed |
| US-20250302837-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-10-02 | — | — | US | disclosed |
| CN-116669723-B | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-09-09 | — | — | CN | disclosed |
| CN-116669723-B | SMTP-7 derivative and application thereof | 福建盛迪医药有限公司 | 2025-09-09 | — | — | CN | disclosed |
| CN-120192332-A | Ring-fused compound, preparation method and application thereof | 先声药业有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250179215-A1 | PLASMIN-BINDING VHHS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-06-05 | — | — | US | disclosed |
| WO-2025104204-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS | ACTICOR BIOTECH (FR) | 2025-05-22 | — | — | WO | disclosed |
| EP-4556492-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS | Acticor Biotech (FR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250154252-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES | ACTICOR BIOTECH (FR) | 2025-05-15 | — | — | US | disclosed |
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA MEDICAL UNIVERSITY (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4519325-A1 | PLASMIN-BINDING VHHS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2025031476-A1 | PREPARATION METHOD FOR SMTP-7 DERIVATIVE AND INTERMEDIATE THEREOF | 上海森辉医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025031476-A1 | PREPARATION METHOD FOR SMTP-7 DERIVATIVE AND INTERMEDIATE THEREOF | 上海森辉医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025031476-A1 | PREPARATION METHOD FOR SMTP-7 DERIVATIVE AND INTERMEDIATE THEREOF | 上海森辉医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| EP-4504201-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2025-02-12 | — | — | EP | disclosed |
| CN-119278042-A | Chymase inhibitors for selective dissolution of thrombi in thrombotic or thromboembolic disorders | 索克普拉健康与人文科学公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4482863-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES | Acticor Biotech (FR) | 2025-01-01 | — | — | EP | disclosed |
| US-20240424093-A1 | DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA | Shimojani, LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | SHOWA UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| EP-4293028-A4 | SMTP-7 DERIVATIVE AND USE THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-12115141-B2 | Diagnosis of diabetes by detecting aggregated amylin in erythrocytes | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-12109265-B2 | Drug regimen for treatment of cerebral ischemia | Shimojani, LLC (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4436567-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118414152-A | Methods of treating neurological and cardiovascular conditions | 阿斯特罗赛特制药公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| JP-2024525998-A | — | ジーシン ファーマシューティカルズ ホンコン リミテッド | 2024-07-16 | — | — | JP | disclosed |
| JP-2024525239-A | — | ジーシン ファーマシューティカルズ ホンコン リミテッド | 2024-07-11 | — | — | JP | disclosed |
| JP-2024525239-A | — | ジーシン ファーマシューティカルズ ホンコン リミテッド | 2024-07-11 | — | — | JP | disclosed |
| CN-118084942-B | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118084942-B | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118084942-B | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240190896-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240190896-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240190896-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| CN-118084942-A | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084942-A | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084942-A | Preparation method of methylated SMTP-7 | 深圳创元生物医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4337193-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | Biogen MA Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337193-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | Biogen MA Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4326258-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4326258-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4326258-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117586283-A | Crystal form of SMTP-7 derivative | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586283-A | Crystal form of SMTP-7 derivative | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586283-A | Crystal form of SMTP-7 derivative | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117295497-A | Pharmaceutical composition for treating cerebral infarction | 渤健马萨诸塞州股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11850232-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | BIOGEN MA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-117295497-A | Pharmaceutical composition for treating cerebral infarction | 渤健马萨诸塞州股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117279634-A | Pharmaceutical composition comprising compound SMTP-7 | 渤健马萨诸塞州股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279634-A | Pharmaceutical composition comprising compound SMTP-7 | 渤健马萨诸塞州股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4293028-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| EP-4293028-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| EP-4293028-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| EP-4289430-A2 | THROMBOLYTIC AGENT AND BEVACIZUMAB FOR TREATMENT OF CEREBRAL ISCHEMIA | Shimojani LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-111936134-B | Pharmaceutical agent and method for treating or preventing kidney disease using the same | 学校法人昭和大学 | 2023-12-08 | — | — | CN | disclosed |
| JP-7381035-B2 | — | 学校法人昭和大学 | 2023-11-15 | — | — | JP | disclosed |
| WO-2023213869-A1 | PLASMIN-BINDING VHHS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023194222-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | SOCPRA SCIENCES SANTÉ HUMAINES S.E.C. (CA) | 2023-10-12 | — | — | WO | disclosed |
| EP-4252752-A1 | DRUG FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE, AND METHOD FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE USING SAID DRUG | Biogen MA Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116761600-A | Medicament for treating or preventing cerebral hemorrhage and method for treating or preventing cerebral hemorrhage using the same | 渤健马萨诸塞州股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116669723-A | SMTP-7 derivative and application thereof | 上海森辉医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116669723-A | SMTP-7 derivative and application thereof | 上海森辉医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116669723-A | SMTP-7 derivative and application thereof | 上海森辉医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023156683-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES | ACTICOR BIOTECH (FR) | 2023-08-24 | — | — | WO | disclosed |
| EP-3565546-B1 | THROMBOLYTIC AGENT AND BEVACIZUMAB FOR TREATMENT OF CEREBRAL ISCHEMIA | SHIMOJANI LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022240810-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | BIOGEN MA INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022240810-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | BIOGEN MA INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022226013-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | BIOGEN MA INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226013-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | BIOGEN MA INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022226013-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | BIOGEN MA INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11440920-B2 | Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method | SHOWA UNIVERSITY (JP) | 2022-09-13 | — | — | US | disclosed |
| US-11440920-B2 | Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method | SHOWA UNIVERSITY (JP) | 2022-09-13 | — | — | US | disclosed |
| WO-2022171151-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | 上海森辉医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022171151-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | 上海森辉医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022171151-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | 上海森辉医药有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| CN-114126711-A | Medicament and method for treating or preventing diabetic complications using the same | 学校法人昭和大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114126711-A | Medicament and method for treating or preventing diabetic complications using the same | 学校法人昭和大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | ALOX5 117/4885APP 2305/4885PTPN1 3029/4885 |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | REN, ATP6V1B1, SLC10A1 | ALOX5 117/4885APP 2305/4885PTPN1 3029/4885 |
| US-20260144792-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | F2R, CMA1, FGB | ALOX5 1730/4885APP 3738/4885PTPN1 1054/4885 |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | PROC, FABP7, SERPINC1 | ALOX5 285/4885APP 592/4885PTPN1 4588/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | ALOX5 71/4885APP 728/4885PTPN1 2665/4885 |
| US-20250302837-A1 | INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS | CMA1, SERPINB1, TPSB2 | ALOX5 748/4885APP 4210/4885PTPN1 2657/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | ALOX5 585/4885APP 1611/4885PTPN1 3210/4885 |
| US-20240238248-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION | PSD, SCN7A, MBOAT7 | ALOX5 3129/4885APP 1162/4885PTPN1 1836/4885 |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, SERPINC1 | ALOX5 285/4885APP 592/4885PTPN1 4588/4885 |
| US-11440920-B2 | Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method | SMS, TST, TES | ALOX5 4649/4885APP 1966/4885PTPN1 3184/4885 |
| US-20240238252-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND SMTP-7 | SMPD1, SMPD3, MBOAT7 | ALOX5 2914/4885APP 695/4885PTPN1 2494/4885 |
| US-11850232-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | PROC, FABP7, SERPINC1 | ALOX5 285/4885APP 592/4885PTPN1 4588/4885 |
| US-20240190896-A1 | SMTP-7 DERIVATIVE AND USE THEREOF | SMPD1, SMPD2, SMPD3 | ALOX5 4154/4885APP 3481/4885PTPN1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.